Alison Oliveto
Title | Professor |
---|
Institution | University of Arkansas for Medical Sciences |
---|
Department | PSY Psychiatry, College of Medicine |
---|
Address | 441 Psychiatric Research Institute 4224 Shuffield Dr. Mail Slot # 843 Little Rock AR 72205
|
---|
Phone | 501-526-8441 |
---|
ORCID
![ORCID Icon](https://uams-triprofiles.uams.edu/profiles/Framework/Images/orcid_16x16(1).gif) | 0000-0001-8574-230X ![Additional info](https://uams-triprofiles.uams.edu/profiles/Framework/Images/info.png) |
---|
vCard | Download vCard |
---|
|
|
|
Interviewer. College of Medicine medical student applicants. | Member, PRI Research Council, Department of Psychiatry and Behavioral Sciences, UAMS | Member. Psychiatry Career Development Committee, UAMS | Interviewer. Executive Director of the National Center for Opioid Research, Arkansas Children’s Research Institute |
|
Overview Historically, my career aims have been to improve upon treatments/ treatment access for substance use disorder as well as generally facilitate research in addiction and beyond. As a trained behavioral pharmacologist, I have had continuous NIH funding since 1993 conducting translational research in addiction, including human laboratory and clinical trials, with a focus on psychostimulant and/or opioid use disorders. In 1996 during my tenure at Yale School of Medicine, I established and directed the Outpatient Treatment Research Program at the West Haven CT Veterans Administration Healthcare System (VAHCS) that administratively involved three institutions (Yale, VAHCS, APT Foundation) to ensure the successful conduct of several medications development human laboratory and clinical trials. In 1998 I became Scientific Director of the NIDA P50 medications development center (T. Kosten, PI) and was responsible for coordinating the mentoring of physician scientists and fellows, overseeing research staff, and consolidating resources to maximize research productivity. When I accepted a faculty position at UAMS in 2004, I moved my research and established an addiction research program in the department of Psychiatry and became Vice Chair for Research in Psychiatry at UAMS. I have been responsible for intramural and extramural grant funding, overseeing the career development of clinician scientists, and establishing a research track for Psychiatry residents. I served in several leadership roles on campus, including in our CTSA-funded Translational Research Institute from 2014-2017. I directed the UAMS CTSA-supported Clinical Trials Unit, transforming culture and processes to maximize efficient, regulatory-compliant and rigorous conduct of multi-site trials. I became Director of Psychiatry's Center for Addiction Research in 2016 and have focused on strategic recruitment of addiction scientists as well as developing synergy among CAR/UAMS faculty. In 2020, I became the UAMS site principal investigator in the NIDA Clinical Trials Network Big/SouthWest Node and am awaiting funding on a NIDA CTN multi-site trial. Meanwhile, my focus has shifted to include drug prevention strategies and am currently leading the Arkansas State Epidemiological Outcomes Workgroup in partnership with state agencies, gathering, analyzing and disseminating trends in substance abuse and related outcomes in order to inform prevention efforts across the state.
Affiliation Member. Society for Scientific Exploration Fellow, College on Problems of Drug Dependence Member, Society for Shamanic Practice
Biography Director. Center for Addiction Research, UAMS Department of Psychiatry
Research Director. UAMS Substance Abuse Treatment Clinic/Center for Addiction Services and Treatment
Team Leader. Arkansas Statewide Epidemiological Outcomes Workgroup
Chair. Dissemination and Publication Committee. NIDA CTN Big South/West Node
St. Lawrence University, Canton, NY | B.S. | 05/1983 | Chemistry/Psychology | Univ of North Carolina, Chapel Hill, NC | PhD | 01/1989 | Exper Psychology/Behav Pharmacology | Univ of Vermont, Burlington, VT | Post-doc | 09/1991 | Human Behavioral Pharmacology |
1979 - 1983 | President's Scholar, St. Lawrence University | 1982 | Psi Chi, Psychology Honorary, St. Lawrence University | 1983 | N.I.M.H. Predoctoral Research Trainee. Department of Psychology, Univ. of North Carolina - Chapel Hill | 1986 - 1988 | N.I.D.A. Predoctoral Research Fellow, Univ of North Carolina - Chapel Hill | 1989 | Travel Award to attend CPDD Meeting, NIDA | 1989 | Travel Award to attend APA Meeting, American Psychological Assoc | 1990 | Travel Award to Attend CPDD Meeting, College on Problems of Drug Dependence | 2008 | Distinguished Alumni Award, Department of Psychology, Univ of North Carolina - Chapel Hill | 2009 | Fellow, College on Problems of Drug Dependence | 2017 - 2020 | Certified Clinical Research Professional, Society of Clinical Research Associates | 2019 | AACAP Outstanding Mentor Award, NIDA | 2022 | RAAD Above & Beyond in Prevention Award , Arkansas Department of Human Services, Division on Aging and Adult Behavioral Health Services |
Teaching Research A behavioral pharmacologist by training, I have been a funded NIH researcher for over four decades, conducting translational research focused mainly on opioid and/or stimulant use disorders. Much of my work has focused on developing human laboratory and clinical trial study designs that serve as models for studying efficacious treatments. For instance, I participated in the development and testing of a methodological advance in human drug discrimination procedures (novel-response option) and applied this methodological advance to a human laboratory model of opioid withdrawal, through which two nonopioid compounds were identified as potential opioid withdrawal treatments. Moreover, my Yale colleague, Dr. Patrick O’Connor, and I piloted the first trial of office-based buprenorphine treatment for opioid use disorder. In addition, I developed in collaboration with Dr. Thomas Kosten a relapse paradigm for stimulant use disorder trials and identified the SSRI sertraline as a potentially efficacious relapse prevention treatment. I also mentored Dr. Michael Mancino (UAMS) on the development of a rigorous amphetamine withdrawal paradigm for his COBRE project (PI: Garcia-Rill) and Dr. Michael Wilson (UAMS) on developing a human laboratory model of “agitation”, which often occurs among methamphetamine users presenting to the ED. I am currently leading the Arkansas Statewide Epidemiology Outcomes Workgroup, monitoring substance use trends and related outcomes to help guide successful substance use prevention efforts in the state. Along these lines, I have been working with Dr. Ronald Thompson (UAMS) on developing and testing the efficacy of an adolescent game-based nonmusical prescription drug use prevention intervention along with a caregiver educational component. Meanwhile, I have returned to my behavioral pharmacology roots, piloting the effects of cannabis in older adults.
NIDA CSP-1036 (S. Gyaw)Mar 1, 2024 - Feb 28, 2027 NIH/NIDA Randomized, CSP-1036: Randomized, Placebo-Controlled, Multi-Site Trial of Extended-Release Naltrexone Injection/Bupropion XL Tablets in the Treatment of Methamphetamine Use Disorder (MURB) Role: Principal Investigator |
| UG1 NIDA CTN-0109 (M. Trivedi/S. Shoptaw)Sep 1, 2023 - Feb 28, 2024 NIH/NIDA Randomized, Placebo-Controlled Trial of Extended-Release Naltrexone and Monthly Extended-Release Injectable Buprenorphine for Cocaine Use Disorder (CURB-2) Role: Principal Investigator |
| J.W. Amis Intramural Pilot Award (A. Oliveto)Jan 1, 2023 - Dec 31, 2024 UAMS Behavioral Pharmacology of Cannabis in Older Adults Role: Principal Investigator |
| 5R21DA053393-02 (OLIVETO, ALISON)Jun 1, 2022 - May 31, 2024 NIH/Nat. Inst. on Drug Abuse - Pass Through: Wake Forest University Effects of ketamine on tobacco use disorder - Resubmission Subaward Role: Principal Investigator |
| 1R21DA053393-01A1 (OLIVETO, ALISON)Jun 1, 2022 - May 31, 2024 NIH/Nat. Inst. on Drug Abuse - Pass Through: Wake Forest University Effects of ketamine on tobacco use disorder - Resubmission Subaward Role: Co-Investigator |
| R01DA048948 (OLIVETO, ALISON)Nov 6, 2021 - May 31, 2024 NIH/Nat. Inst. on Drug Abuse - Pass Through: Wake Forest University Distress Tolerance and Smoking Cessation Role: Principal Investigator |
| 5R01DA048948-05 (OLIVETO, ALISON)Nov 6, 2021 - May 31, 2024 NIH/Nat. Inst. on Drug Abuse - Pass Through: Wake Forest University Distress Tolerance and Smoking Cessation Role: Co-Investigator |
| 3UG1DA013035-21S3 (OLIVETO, ALISON)Jul 1, 2021 - Feb 28, 2026 NIH/Nat. Inst. on Drug Abuse - Pass Through: New York University CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) Role: Principal Investigator |
| UG1DA013035 (OLIVETO, ALISON)Jul 1, 2021 - Feb 28, 2026 NIH/Nat. Inst. on Drug Abuse - Pass Through: New York University CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) Role: Principal Investigator |
| TI083287-01 (Motley-Bledsoe, Deborah)Apr 1, 2021 - Sep 30, 2023 SAMHSA - Pass Through Arkansas Department of Human Services Medication Assisted Treatment for Opioid Use Disorders among Rural and Uninsured or Underinsured Arkansans Role Description: Site Principal Investigator: Michael Mancino, MD
To establish and expand medication assisted treatment (MAT) services for opioid use disorders (OUD) within the state by compensating facilities across the state to provide MAT to uninsured and underinsured patients with OUD.
Role: Evaluator Role: Other Key Personnel |
| B08 TI083061 (Barnes, Tenesha)Oct 1, 2020 - Sep 30, 2024 SAMHSA - Pass Through Arkansas Department of Human Services Substance Abuse Bock Grant Role Description: The aims of this subcontract from the Arkansas Department of Human Services Division on Aging and Adult Behavioral Health Services and the University of Arkansas at Little Rock School of Social Work/MidSOUTH are to compile, harmonize, analyze and disseminate substance use and substance use-related data among young adults, working closely with state agencies and other stakeholders, in order to guide prevention efforts for this age group in the state of Arkansas.
Role: Project Team Leader Role: Other Key Personnel |
| UG1DA020024 (OLIVETO, ALISON)Jun 1, 2020 - Feb 28, 2025 NIH/Nat. Inst. on Drug Abuse - Pass Through: University of Texas Southwestern Medical Center Clinical Trials Network: The Big South/West Node Role: Co-Investigator |
| SP080990 (Barnes, Tenesha)Oct 1, 2019 - Sep 30, 2023 SAMHSA - Pass Through Arkansas Department of Human Services Partnership for Success: Statewide Epidemiological Outcomes Workgroup for Arkansas Role Description: The aims of this subcontract from the Arkansas Department of Human Services Division on Aging and Adult Behavioral Health Services and the University of Arkansas MidSOUTH are to compile, harmonize, analyze and disseminate substance use and substance use-related data among youth and adults, working closely with state agencies and other stakeholders, in order to guide prevention efforts in the state of Arkansas.
Role: SEOW Team Leader Role: Other Key Personnel |
| COPH Center for Tobacco Studies (OLIVETO, ALISON)Mar 6, 2019 - Jan 30, 2022 UAMS Internal Research Awards No FP attached Role: Principal Investigator |
| UAMS Internal Funding (Addicott, Merideth)Jan 15, 2019 - Oct 31, 2021 UAMS Center for the Study of Tobacco The Effects of Ketamine on Tobacco Use Role Description: The overarching aim of this project is to obtain preliminary data on the safety and impact of ketamine on tobacco craving and use in recently abstinent smokers. Role: Co-Investigator |
| TRI FY19 (NESMITH, CLARE)Jan 15, 2019 - Jan 31, 2021 UAMS Intramural Grant (CTSA) No FP attached Role: Principal Investigator |
| UAMS/TRI Internal Pilot Funds (Oliveto, Alison)Jan 14, 2019 - Apr 30, 2020 UAMS/Translational Research Institute Gamified Intervention to Prevent Adolescent Opioid Misuse Role Description: The overarching goal of this project is to develop a prototype refusal skill gamified opioid misuse prevention module that can be delivered via several platforms (e.g., smartphone, tablet, computer) and determining its initial acceptability and developmental appropriateness in grade-based cohorts of 8th and 11th graders. Role: Principal Investigator |
| UAMS Internal Funding (Larson-Prior, Linda)Jan 14, 2019 - Jan 31, 2020 UAMS/Translational Research Institute The impact of buprenorphine on sleep, mood and cognition in opioid use disorder patients participating in a medication assisted treatment program Role Description: The overarching goal of this project is to determine whether severity of baseline sleep disruption impacts treatment retention and treatment phase progression; sleep normalizes over a 6 month treatment period; and whether sleep normalization reduces mood and cognitive dysfunction in a population of patients who are being treated with buprenorphine as part of medication assisted treatment for opioid use disorder. Role: Co-Investigator |
| R21DA045246 (WRIGHT, PATRICIA B)Sep 30, 2018 - Aug 31, 2021 NIH Improving Treatment Strategies for Prescription Opioid Use Disorder- Resubmission Role: Co-Investigator |
| CFDA 93.788 (Motley-Bledsoe, Deborah)Dec 15, 2017 - Sep 30, 2020 SAMHSA - Pass Through Arkansas Department of Human Services Expanding Access to Medication Assisted Treatment Across the State of Arkansas Role Description: This project proposes to increase the number of providers that are waivered providers for buprenorphine and also seeks to increase support for providers engaged in MAT utilizing traditional telemedicine support as well as a Project ECHO approach to enhance the independence of MAT clinicians.
Site Principal Investigator: Michael Mancino, MD/Project Principal Investigator: Michael Wilson, MD
The aims of this project are to 1) expand distribution of Narcan rescue medication to those at high risk for opioid overdose as well as those who know of those at risk for opioid overdose and 2) facilitate transition of ED patients presenting to the ED with opioid use disorder to medication assisted treatment by inducting patients on buprenorphine and transferring them to a local substance abuse treatment clinic for longer-term care. Role: Other Key Personnel |
| U54TR001629 (JAMES, LAURA P)Sep 26, 2017 - Aug 31, 2019 NIH Expanding Translational Research in Arkansas Role: Co-Investigator |
| R01DA039088 (OLIVETO, ALISON)Jul 15, 2015 - May 31, 2021 NIH/Nat. Inst. on Drug Abuse Improving Treatment Outcomes for Prescription Opioid Dependence - Continuation - Continuation - Continuation - Continuation Role: Principal Investigator |
| R01DA039088 (OLIVETO, ALISON)Jul 15, 2015 - May 31, 2021 NIH Improving Treatment Outcomes for Prescription Opioid Dependence Role: Principal Investigator |
| R01DA039088 (OLIVETO, ALISON)Jul 15, 2015 - May 31, 2021 NIH/Nat. Inst. on Drug Abuse Improving Treatment Outcomes for Prescription Opioid Dependence - Continuation - Continuation - Continuation - Continuation Role: Principal Investigator |
| R21DA034824 (MANCINO, MICHAEL J)Aug 1, 2013 - Jul 31, 2016 NIH Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence Role: Co-Investigator |
| R21DA035325 (OLIVETO, ALISON)Apr 15, 2013 - Mar 31, 2016 NIH/Nat. Inst. on Drug Abuse Improving Buprenorphine Detoxification Outcomes with Isradipine Role: Principal Investigator |
| R01AA016917 (OLIVETO, ALISON)Jun 5, 2012 - Jul 31, 2012 NIH/Nat. Inst. on Alcohol Abuse & Alcoholism - Pass Through: Dartmouth College Family Bases Contingency Management for Adolescent Alcohol Abuse Role: Principal Investigator |
| R01AA016917 (OLIVETO, ALISON)Jun 5, 2012 - Jul 31, 2012 NIH/Nat. Inst. on Alcohol Abuse & Alcoholism - Pass Through: Dartmouth College Family Bases Contingency Management for Adolescent Alcohol Abuse Role: Principal Investigator |
| R21DA031837 (OLIVETO, ALISON)May 1, 2012 - Aug 31, 2015 NIH/Nat. Inst. on Drug Abuse Impact of CYP2D6 Phenotype on Response to Methamphetamine in Humans Role: Principal Investigator |
| R21DA029842 (OLIVETO, ALISON)Aug 1, 2011 - Jun 30, 2015 NIH/Nat. Inst. on Drug Abuse Clinical Efficacy of Atomoxetine for Methamphetamine Dependence Role: Principal Investigator |
| P50DA018197 (OLIVETO, ALISON)Sep 1, 2009 - May 31, 2014 NIH/Nat. Inst. on Drug Abuse - Pass Through: Baylor College of Medicine Efficacy of Carvedilol in Recently-Abstinent Psychostimulant Dependent Patients Role: Principal Investigator |
| R01DA026916 (GENTRY, WILLIAM)Sep 1, 2009 - Jul 31, 2013 NIH/Nat. Inst. on Drug Abuse Monoamine Antagonist Therapies for Methamphetamine Abuse Role: Co-Investigator |
| R01DA012997 (W. Bickel)Dec 1, 2004 - Mar 31, 2006 NIH/NIDA Improving Combined Buprenorphine-Behavioral Treatment Role: Co-Investigator |
| P20RR020146 (GARCIA-RILL, EDGAR E.)Sep 16, 2004 - Apr 30, 2014 NIH Center for Translational Neuroscience Role: Co-Investigator |
| P50-DA12762 (T.R. Kosten)Sep 1, 2004 - Aug 31, 2009 NIH/NIDA Yale Medications Development Center (Cocaine Pharmacotherapies for Comorbid Populations) Project: Clinical Efficacy of Sertraline Augmented with GABA Agents for Cocaine Dependence Role: Principal Investigator |
| R01DA014388 (OLIVETO, ALISON)Jul 9, 2001 - Jun 30, 2006 NIH/Nat. Inst. on Drug Abuse Behavioral Effects of GHB in Healthy Volunteers Role: Principal Investigator |
| R01DA013441 (OLIVETO, ALISON)Jul 1, 2000 - Dec 31, 2012 NIH/Nat. Inst. on Drug Abuse Disulfiram for Cocaine Abuse in Methadone-Maintained Patients Role: Principal Investigator |
| R01DA010017 (OLIVETO, ALISON)Sep 30, 1997 - Nov 30, 2012 NIH/Nat. Inst. on Drug Abuse Opioid Antagonist Discrimination: A Model of Withdrawal Role: Principal Investigator |
Outreach Bibliographic The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System.
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
Don't see publications published under other names? Login to add alternative names.
-
Tsai PF, Oliveto AH, Landes RD, Mancino MJ. Characteristics of patients undergoing medication-assisted -treatment for opioid use disorder and their interest in Tai Chi practice. J Opioid Manag. 2023 Jul-Aug; 19(4):329-341. PMID: 37644791.
-
Addicott MA, Oliveto AH, Daughters SB. Smoking status affects cognitive, emotional and neural-connectivity response to distress-inducing auditory feedback. Drug Alcohol Depend. 2023 05 01; 246:109855. PMID: 37028104.
-
Thompson, Jr., R.G., Mancino, M.J., Kumar, N., Gokarakonda, S., Mendiratta, P., Bollinger, M., Oliveto A.H. Medical Marijuana: What Arkansas Adults Need to Know [Spanish version: Marihuana medicinal: lo que los adultos en Arkansas necesitan saber]. University of Arkansas for Medical Sciences, University of Arkansas at Little Rock MidSouth, and the Arkansas Department of Human Services. University of Arkansas for Medical Sciences, Little Rock, AR. 2023.
-
Oliveto AH, Porter A, Thostenson J, Bollinger M . Arkansas State Epidemiological Outcomes Workgroup: 2022 Arkansas Young Adult State of Wellbeing. Little Rock: Psychiatric Research Institute, University of Arkansas for Medical Sciences. 2023.
-
Bollinger M, Thostenson J, Porter A, Oliveto AH. Arkansas State Epidemiological Outcomes Workgroup: 2022 Arkansas State Epidemiological Profile of Substance Use. Little Rock: Psychiatric Research Institute, University of Arkansas for Medical Sciences. 2023.
-
Oliveto AH, Porter A, Thostenson J, Bollinger M . Arkansas State Epidemiological Outcomes Workgroup: 2022 Arkansas Young Adult State of Wellbeing. Little Rock: Psychiatric Research Institute, University of Arkansas for Medical Sciences. 2023.
-
Oliveto AH, Porter A, Thostenson J, Bollinger M . Arkansas State Epidemiological Outcomes Workgroup: 2022 Arkansas Young Adult State of Wellbeing. Little Rock: Psychiatric Research Institute, University of Arkansas for Medical Sciences. 2023.
-
Oliveto AH, Thostenson J, Porter A, Bollinger M. Arkansas State Epidemiological Outcomes Workgroup: 2023 Arkansas State Epidemiological Profile of Substance Use. Little Rock: Psychiatric Research Institute, University of Arkansas for Medical Sciences. 2023.
-
Gokarakonda SB, Boydstun JM, Yilanli M, Han X, Kumar N, Oliveto AH, Mancino MJ. Impact of state and trait anxiety severity on retention and phase advancement in an outpatient buprenorphine treatment program. Am J Addict. 2022 05; 31(3):219-225. PMID: 35243715.
-
Oliveto AH, Wright P, Kumar N, Gokarakonda S, Fischer-Laycock I, Williams J, Thompson RG. Acceptability of a Game-Based Intervention to Prevent Adolescent Prescription Opioid Misuse. Games Health J. 2022 Apr; 11(2):104-116. PMID: 35167352.
-
Gokarakonda, S., Thompson Jr., R.G., Mancino, M.J., Kumar, N. Mendiratta, P., Bollinger, M., Oliveto, A.H. Medical Marijuana: What Arkansas Kids Need to Know [Spanish version: Informacion Sobre La Marihuana Medicinal: lo que los ninos de Arkansas necesitan saber]. University of Arkansas for Medical Sciences, University of Arkansas at Little Rock MidSouth, and the Arkansas Department of Human Services. University of Arkansas for Medical Sciences, Little Rock, AR. 2022.
-
Oliveto, A.H., Bollinger, M., Basri, T., Thostenson, J. Most Arkansas Young Adults do not use Marijuana. [Spanish version: En Arkansas, la mayoría de los adultos jóvenes no usan marihuana]. University of Arkansas for Medical Sciences, University of Arkansas at Little Rock MidSouth, and the Arkansas Department of Human Services. University of Arkansas for Medical Sciences, Little Rock, AR. 2022.
-
Oliveto, A.H., Bollinger, M., Basri, T., Thostenson, J. Most Teens in Arkansas do not use Marijuana. [Spanish version: La mayoría de los jovenes en Arkansas no usan marihuana]. University of Arkansas for Medical Sciences, University of Arkansas at Little Rock MidSouth, and the Arkansas Department of Human Services. University of Arkansas for Medical Sciences, Little Rock, AR. 2022.
-
4. Gokarakonda S, Thompson, Jr., RG, Mancino MJ, Kumar N, Mendiratta P, Bollinger M, and Oliveto AH. Medical Marijuana: What Arkansas Teens Need to Know [Spanish version: Marihuana Medicinal: Lo que los Adolescentes de Arkansas Necesitan Saber]. University of Arkansas for Medical Sciences, University of Arkansas at Little Rock MidSouth, and the Arkansas Department of Human Services. University of Arkansas for Medical Sciences, Little Rock, AR. 2022.
-
Oliveto, A.H., Mancino, M.J., Kumar, N., Gokarakonda, S., Mendiratta, P., Bollinger, M., Thompson, Jr., R.G. . Medical Marijuana: What Caregivers Need to Know [Spanish version: Lo que los cuidadores deben saber sobre la marihuana medicinal]. University of Arkansas for Medical Sciences, University of Arkansas at Little Rock MidSouth, and the Arkansas Department of Human Services. University of Arkansas for Medical Sciences, Little Rock, AR. 2022.
-
Bollinger M, Thostenson JD Oliveto AH. Arkansas State Epidemiological Outcomes Workgroup: 2021 Arkansas Young Adult State of Wellbeing. Little Rock: Psychiatric Research Institute, University of Arkansas for Medical Sciences. 2022.
-
Bollinger M, Thostenson J, Porter A, Oliveto AH. Arkansas State Epidemiological Outcomes Workgroup: 2021 Arkansas State Epidemiological Profile of Substance Use. Little Rock: Psychiatric Research Institute, University of Arkansas for Medical Sciences. Downloadable from:. 2022.
-
Thompson RG, Oliveto A, Thostenson JD, Wilson MP, McGaugh J, Mancino MJ. Utility of a controlled amphetamine withdrawal paradigm among adults who use methamphetamine: A pilot clinical trial. J Psychopharmacol. 2021 11; 35(11):1420-1430. PMID: 34697965.
-
Phillips SJ, Oliveto A, Mancino MJ, Hendrickson HP. Development and validation of a rapid liquid chromatography/tandem mass spectrometry method to quantitate gabapentin and buprenorphine in human serum. Rapid Commun Mass Spectrom. 2021 Jul 31; 35(14):e9104. PMID: 33860565.
-
Wilson MP, Kaur J, Blake L, Oliveto AH, Thompson RG, Pyne JM, Wolf L, Walker AP, Waliski AD, Nordstrom K. Adherence to guideline creation recommendations for suicide prevention in the emergency department: A systematic review. Am J Emerg Med. 2021 Dec; 50:553-560. PMID: 34547697.
-
Boateng BA, Oliveto AH, Bailey M, Hunter-Lewis M, Young J, James LP. Utility of Protocol Development Software for IRB Protocol Development: Experiences from one Institution. SOCRA Source. 2021 Feb; 107:39-42. PMID: 34646090.
-
Oliveto, A.H., Bollinger, M., Thostenson, J. Using Methamphetamine (Meth): Know the Risks. [Spanish version: Usar Metanfetamina (Meta): Conozca los Riesgos.] University of Arkansas for Medical Sciences, University of Arkansas at Little Rock MidSouth, and the Arkansas Department of Human Services. University of Arkansas for Medical Sciences, Little Rock, AR. 2021.
-
Oliveto AH, Thostenson J, Bollinger M. Arkansas State Epidemiological Outcomes Workgroup: A Companion Guide to the 2020 Arkansas State Epidemiological Profile of Substance Use. Regional Key Findings. Little Rock: Psychiatric Research Institute, University of Arkansas for Medical Sciences. 2021.
-
Allison Schneider BS, Samuel Mullinax BA, Oliveto AH, Acheson A, Wilson MP. In reply: Bias risk in systematic reviews. Am J Emerg Med. 2021 07; 45:600-601. PMID: 33390297.
-
Kumar N, Mancino MJ, Thostenson JD, McGaugh J, Oliveto AH. Feasibility and Preliminary Efficacy of Isradipine During Outpatient Buprenorphine Stabilization and Detoxification: A Pilot Randomized, Placebo-Controlled Trial. Subst Abuse. 2020; 14:1178221820970926. PMID: 33281447.
-
Schneider A, Mullinax S, Hall N, Acheson A, Oliveto AH, Wilson MP. Intramuscular medication for treatment of agitation in the emergency department: A systematic review of controlled trials. Am J Emerg Med. 2021 08; 46:193-199. PMID: 33071100.
-
Chalmers CE, Mullinax S, Brennan J, Vilke GM, Oliveto AH, Wilson MP. Corrigendum to "Screening Tools Validated in the Outpatient Pain Management Setting Poorly Predict Opioid Misuse in the Emergency Department: A Pilot Study" [J Emerg Med. 2019;56(6):601-10]. J Emerg Med. 2020 Jan; 58(1):174. PMID: 37046426.
-
Bollinger M, Thostenson J, Oliveto AH. Arkansas State Epidemiological Outcomes Workgroup: 2020 Arkansas State Epidemiological Profile of Substance Use. Little Rock: Psychiatric Research Institute, University of Arkansas for Medical Sciences. 2020.
-
Thompson, Jr., R.G., Mancino, M.J., Kumar, N., Gokarakonda, S., Mendiratta, P., Bollinger, M., Porter, A., Oliveto, A.O. Medical Marijuana: What Arkansas Physicians Need to Know. University of Arkansas for Medical Sciences, University of Arkansas at Little Rock MidSouth, and the Arkansas Department of Human Services. University of Arkansas for Medical Sciences, Little Rock, AR. 2020.
-
Wilson MP, Cucciare MA, Porter A, Chalmers CE, Mullinax S, Mancino M, Oliveto AH. The utility of a statewide prescription drug-monitoring database vs the Current Opioid Misuse Measure for identifying drug-aberrant behaviors in emergency department patients already on opioids. Am J Emerg Med. 2020 03; 38(3):503-507. PMID: 31221474.
-
Chalmers CE, Mullinax S, Brennan J, Vilke GM, Oliveto AH, Wilson MP. Screening Tools Validated in the Outpatient Pain Management Setting Poorly Predict Opioid Misuse in the Emergency Department: A Pilot Study. J Emerg Med. 2019 Jun; 56(6):601-610. PMID: 31043338.
-
Oliveto, A. and Sclazo, D. Clinical Researcher’s Handbook: A Survival Guide. Tips for maintaining research compliance and collecting high quality research data. Translational Research Institute, University of Arkansas for Medical Sciences. 2019.
-
Oliveto, A.H, Thompson, R.G., and Wright, P.B. Safe prescribing of Opioids for Pain Management in Children and Adolescents: Tips for Healthcare Providers. University of Arkansas for Medical Sciences, University of Arkansas at Little Rock MidSouth, and the Arkansas Department of Human Services. University of Arkansas for Medical Sciences, Little Rock, AR. 2019.
-
Oliveto, A.H, Thompson, R.G., and Wright, P.B. . Pain Medicine Guide for Kids: How to safely use pain medicine. [Spanish version: Guía de Medicina para el Dolor para Niños: Cómo tomar medicina para el dolor de forma segura]. University of Arkansas for Medical Sciences, University of Arkansas at Little Rock MidSouth, and the Arkansas Department of Human Services. University of Arkansas for Medical Sciences, Little Rock, AR. 2019.
-
Oliveto, A.H, Thompson, R.G., and Wright, P.B. Prescription Pain Medicine Guide for Teens: How to safely use prescription opioid medicines to treat your pain [Spanish version: Guía de Medicina para el Dolor Recetada para Adolescentes Cómo tomar medicinas de opioides recetadas para tratar tu dolor de forma segura]. University of Arkansas for Medical Sciences, University of Arkansas at Little Rock MidSouth, and the Arkansas Department of Human Services. University of Arkansas for Medical Sciences, Little Rock, AR. 2019.
-
Oliveto, A.H, Thompson, R.G., and Wright, P.B. . Helping Your Child Safely Take Prescription Pain Medicine: The Caregiver’s Guide [Spanish version: Ayudando a Su Niño a Tomar Medicina con Precaución, Recetada por el Dolor: La Guía para el Cuidador.] University of Arkansas for Medical Sciences, University of Arkansas at Little Rock MidSouth, and the Arkansas Department of Human Services. 2019.
-
Nahata R, Mancino MJ, Thostenson J, Oliveto AH. Survey of Treatment Preferences for Opioid Use Disorder. Jacobs J Addict Ther. 2018; 5(3). PMID: 31131330.
-
Bashiri M, Mancino MJ, Stanick VA, Thostenson J, Kosten TR, Oliveto AH. Moderators of response to sertraline versus placebo among recently abstinent, cocaine dependent patients: A retrospective analysis of two clinical trials. Am J Addict. 2017 Dec; 26(8):807-814. PMID: 29115703.
-
Bashiri M, Greenfield LJ, Oliveto A. Telemedicine Interest for Routine Follow-Up Care Among Neurology Patients in Arkansas. Telemed J E Health. 2016 06; 22(6):514-8. PMID: 26684500.
-
Mancino MJ, McGaugh J, Chopra MP, Guise JB, Cargile C, Williams DK, Thostenson J, Kosten TR, Sanders N, Oliveto A. Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. J Clin Psychopharmacol. 2014 Apr; 34(2):234-9. PMID: 24525654.
-
Sanders NC, Mancino MJ, Gentry WB, Guise JB, Bickel WK, Thostenson J, Oliveto AH. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Exp Clin Psychopharmacol. 2013 Aug; 21(4):294-302. PMID: 23855333.
-
Atkinson TS, Sanders N, Mancino M, Oliveto A. Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients. J Addict Med. 2013 Jul-Aug; 7(4):243-8. PMID: 23648640.
-
Oliveto A, Mancino M, Sanders N, Cargile C, Benjamin Guise J, Bickel W, Brooks Gentry W. Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure. Eur J Pharmacol. 2013 Sep 05; 715(1-3):424-35. PMID: 23524089.
-
Oliveto A, Poling J, Mancino MJ, Williams DK, Thostenson J, Pruzinsky R, Gonsai K, Sofuoglu M, Gonzalez G, Tripathi S, Kosten TR. Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction. 2012 Jan; 107(1):131-41. PMID: 21707811.
-
Mancino MJ, Gentry BW, Feldman Z, Mendelson J, Oliveto A. Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study. Am J Drug Alcohol Abuse. 2011 Mar; 37(2):131-6. PMID: 21219261.
-
Oliveto A, Poling J, Mancino MJ, Feldman Z, Cubells JF, Pruzinsky R, Gonsai K, Cargile C, Sofuoglu M, Chopra MP, Gonzalez-Haddad G, Carroll KM, Kosten TR. Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend. 2011 Jan 15; 113(2-3):184-91. PMID: 20828943.
-
Oliveto A, Gentry WB, Pruzinsky R, Gonsai K, Kosten TR, Martell B, Poling J. Behavioral effects of gamma-hydroxybutyrate in humans. Behav Pharmacol. 2010 Jul; 21(4):332-42. PMID: 20526195.
-
Mancino MJ, McGaugh J, Feldman Z, Poling J, Oliveto A. Effect of PTSD diagnosis and contingency management procedures on cocaine use in dually cocaine- and opioid-dependent individuals maintained on LAAM: a retrospective analysis. Am J Addict. 2010 Mar-Apr; 19(2):169-77. PMID: 20163389.
-
Oliveto A, Pruzinsky R, Poling J, Gentry WB, Martell B, Gonsai K, Kosten TR. Behavioral effects of GHB in humans. Behavioural Pharmacology. 2010; 21(4):332-42.
-
McGaugh J, Mancino MJ, Feldman Z, Chopra MP, Gentry WB, Cargile C, Oliveto A. Open-label pilot study of modafinil for methamphetamine dependence. J Clin Psychopharmacol. 2009 Oct; 29(5):488-91. PMID: 19745650.
-
Chopra MP, Feldman Z, Mancino MJ, Oliveto A. Sex and opioid maintenance dose influence response to naloxone in opioid-dependent humans: a retrospective analysis. Pharmacol Biochem Behav. 2008 Oct; 90(4):787-96. PMID: 18585405.
-
Chopra M.P, Feldman Z.L, Mancino M.J, Oliveto A. Response to naloxone versus placebo in opioid-dependent humans responding under a naloxone discrimination procedure: influences of sex and opioid maintenance dose. Pharmacology, Biochemistry and Behavior. 2008; 90(4):787-96.
-
Sofuoglu M, Poling J, Gonzalez G, Gonsai K, Oliveto A, Kosten TR. Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study. Exp Clin Psychopharmacol. 2007 Oct; 15(5):453-60. PMID: 17924779.
-
Poling J, Pruzinsky R, Kosten TR, Gonsai K, Sofuoglu M, Gonzalez G, Oliveto A. Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients. Am J Addict. 2007 May-Jun; 16(3):187-94. PMID: 17612822.
-
Gonz?lez G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, Kosten TR. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend. 2007 Feb 23; 87(1):1-9. PMID: 16930857.
-
Kosten TR, Scanley BE, Tucker KA, Oliveto A, Prince C, Sinha R, Potenza MN, Skudlarski P, Wexler BE. Cue-induced brain activity changes and relapse in cocaine-dependent patients. Neuropsychopharmacology. 2006 Mar; 31(3):644-50. PMID: 16123763.
-
Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, Martell B, Kosten TR. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry. 2006 Feb; 63(2):219-28. PMID: 16461866.
-
Oliveto A, Poling J, Sevarino KA, Gonsai KR, McCance-Katz EF, Stine SM, Kosten TR. Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. Drug Alcohol Depend. 2005 Aug 01; 79(2):157-65. PMID: 16002025.
-
Kosten T, Sofuoglu M, Poling J, Gonsai K, Oliveto A. Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response. Am J Addict. 2005 Jan-Feb; 14(1):8-17. PMID: 15804873.
-
Hughes JR, Oliveto AH, Riggs R, Kenny M, Liguori A, Pillitteri JL, MacLaughlin MA. Concordance of different measures of nicotine dependence: two pilot studies. Addict Behav. 2004 Nov; 29(8):1527-39. PMID: 15451122.
-
Oliveto A, Poling J, Kosten TR, Gonsai K. Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure. Eur J Pharmacol. 2004 May 03; 491(2-3):157-68. PMID: 15140632.
-
Gonzalez G, Oliveto A, Kosten TR. Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother. 2004 Apr; 5(4):713-25. PMID: 15102558.
-
Kosten T, Falcioni J, Oliveto A, Feingold A. Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone. Am J Addict. 2004 Mar-Apr; 13(2):191-201. PMID: 15204669.
-
Kosten T.R, Falcioni J, Oliveto A, Feingold A. Depression predicts poor treatment response with desipramine and methadone or buprenorphine among cocaine and opioid dependent patients. American Journal on the Addictions. 2004; 13(2):191-201.
-
Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, George TP, Kosten TR. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction. 2003 Nov; 98(11):1625-32. PMID: 14616189.
-
Gonzalez G, Feingold A, Oliveto A, Gonsai K, Kosten TR. Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management. Am J Drug Alcohol Abuse. 2003 Aug; 29(3):497-514. PMID: 14510037.
-
Oliveto A, Benios T, Gonsai K, Feingold A, Poling J, Kosten TR. D-cycloserine-Naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure. Exp Clin Psychopharmacol. 2003 Aug; 11(3):237-46. PMID: 12940503.
-
Sofuoglu M, Singha A, Kosten TR, McCance-Katz FE, Petrakis I, Oliveto A. Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. Pharmacol Biochem Behav. 2003 Jul; 75(4):801-8. PMID: 12957222.
-
Kosten T, Oliveto A, Feingold A, Poling J, Sevarino K, McCance-Katz E, Stine S, Gonzalez G, Gonsai K. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 2003 Jun 05; 70(3):315-25. PMID: 12757969.
-
Kosten T, Poling J, Oliveto A. Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients. Addiction. 2003 May; 98(5):665-71. PMID: 12751984.
-
Kosten TR, Oliveto A, Sevarino KA, Gonsai K, Feingold A. Ketoconazole increases cocaine and opioid use in methadone maintained patients. Drug Alcohol Depend. 2002 Apr 01; 66(2):173-80. PMID: 11906804.
-
Feingold A, Oliveto A, Schottenfeld R, Kosten TR. Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers. Am J Addict. 2002; 11(2):111-23. PMID: 12028741.
-
Gonzalez G, Oliveto A, Kosten TR. Treatment of heroin (diamorphine) addiction: current approaches and future prospects. Drugs. 2002; 62(9):1331-43. PMID: 12076182.
-
Oliveto A, Sevarino K, McCance-Katz E, Feingold A. Butorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure. Pharmacol Biochem Behav. 2002 Jan-Feb; 71(1-2):85-96. PMID: 11812511.
-
Oliveto A.H, Rosen M, Kosten T.A, Hameedi F, Woods S, Kosten T.R. Naloxone discrimination in opioid-dependent humans under a novel-response discrimination procedure. Experimental and Clinical Psychopharmacology. 1998; (6):169-178.
-
Oliveto A.H, Kosten T. R. New Treatments for Opiate Dependence. Buprenorphine. 1997.
-
Hughes J.H, Oliveto A.H, Higgins S.T, Bickel W.K, Terry S.Y. Saying vs. doing and other methodological issues in the study of human drug self-administration. Experimental and Clinical Psychopharmacology. 1996; (4):234-238.
-
Best S.E, Oliveto A.H, Kosten T.R. Opioid Addiction: Recent Advances in Detoxification and Maintenance Therapy. CNS Drugs. 1996; (6):301-304.
-
Kamien JB, Bickel WK, Oliveto AH, Higgins ST, Hughes JR, Richards AT, Badger GJ. Placebo-effects contribute to differences in the acquisition of drug discrimination by humans: a retrospective analysis. Behav Pharmacol. 1995; 6(2):187 - 194.
-
Hale K.L, Hughes J.R, Oliveto A.H, Higgins S.T. Caffeine self-administration and subjective effects in adolescents. Experimental and Clinical Psychopharmacology. 1995; (3):364-370.
-
Hughes, J.R, Oliveto A.H, Bickel W.K, Higgins S.T, Badger G.J. The ability of low doses of caffeine to serve as reinforcers in humans: A replication. Experimental and Clinical Psychopharmacology. 1995; (3):1-6.
-
Kamien JB, Bickel WK, Oliveto AH, Smith BJ, Higgins ST, Hughes JR, Badger GJ. Triazolam discrimination by humans under a novel response procedure: effects of buspirone and lorazepam. Behav Pharmacol. 1994; 5(3):315 - 325.
-
Oliveto A.H, Kosten T.R, Schottenfeld R, Ziedonis D, Falcioni J. Cocaine use in buprenorphine- vs methadone-maintained cocaine users. American Journal of Addictions. 1994; (3):43-48.
-
Oliveto AH, Bickel WK, Hughes JR, Terry SY, Higgins ST, Badger GJ. Pharmacological specificity of the caffeine discriminative stimulus in humans: effects of theophylline, methylphenidate and buspirone. Behav Pharmacol. 1993; 4(3):237 - 246.
-
Hudnell, H.K. and Oliveto, A.H. An Independent Study Course in Introductory Psychology. University of North Carolina at Chapel Hill. 1988.
-
McGaugh, J.D., Mancino, M., Gentry, W.B., Chopra, M., Cargile, C., Oliveto A. Open label modafinil for methamphetamine dependence: Safety and tolerability. 70th Annual Meeting of the College on Problems of Drug Dependence.
-
Oliveto A, Feldman Z, Mancino, M.J. Alcohol dependence diagnosis influences response to disulfiram in dually cocaine- and opioid-dependent humans maintained on methadone. 70th Annual Meeting of the College on Problems of Drug Dependence.
-
Mancino, M.J., Feldman, Z., Oliveto A. Gender differences in response to disulfiram treatment for cocaine dependence in methadone-stabilized opioid- and cocaine-dependent individuals. 70th Annual Meeting of the College on Problems of Drug Dependence.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
1993 | 1 | 1994 | 2 | 1995 | 3 | 1996 | 2 | 1997 | 1 | 1998 | 1 | 2002 | 4 | 2003 | 6 | 2004 | 5 | 2005 | 2 | 2006 | 3 | 2007 | 2 | 2008 | 2 | 2009 | 1 | 2010 | 4 | 2011 | 2 | 2013 | 3 | 2014 | 1 | 2015 | 1 | 2017 | 1 | 2018 | 1 | 2019 | 7 | 2020 | 6 | 2021 | 6 | 2022 | 9 | 2023 | 8 |
To return to the timeline, click here.
|
Oliveto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts ![Expand Description](https://uams-triprofiles.uams.edu/profiles/Framework/Images/info.png) Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors ![Expand Description](https://uams-triprofiles.uams.edu/profiles/Framework/Images/info.png) People in Profiles who have published with this person. _
Similar People ![Expand Description](https://uams-triprofiles.uams.edu/profiles/Framework/Images/info.png) People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|